Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2016 Feb 25

PMID 26908726

Citations 17

Authors

Thanyawee Puthanakit

Li-Min Huang

Cheng-Hsun Chiu

Ren-Bin Tang

Tino F Schwarz

Susanna Esposito

Louise Frenette

Carlo Giaquinto

Shelly McNeil

Paul Rheault

Paolo Durando

Michael Horn

Maximilian Klar

Sylviane Poncelet

Stephanie De Simoni

Damien Friel

Benoit De Muynck

Pemmaraju V Suryakiran

Marjan Hezareh

Dominique Descamps

Florence Thomas

Frank Struyf

Affiliations

Soon will be listed here.

Abstract

Background: This randomized, open trial compared regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years with one including 3 doses (3D) in women aged 15-25 years.

Methods: Girls aged 9-14 years were randomized to receive 2D at months 0 and 6 (M0,6; (n = 550) or months 0 and 12 (M0,12; n = 415), and women aged 15-25 years received 3D at months 0, 1, and 6 (n = 482). End points included noninferiority of HPV-16/18 antibodies by enzyme-linked immunosorbent assay for 2D (M0,6) versus 3D (primary), 2D (M0,12) versus 3D, and 2D (M0,6) versus 2D (M0,12); neutralizing antibodies; cell-mediated immunity; reactogenicity; and safety. Limits of noninferiority were predefined as <5% difference in seroconversion rate and <2-fold difference in geometric mean antibody titer ratio.

Results: One month after the last dose, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6). Geometric mean antibody titer ratios (3D/2D) for HPV-16 and HPV-18 were 1.09 (95% confidence interval, .97-1.22) and 0.85 (.76-.95) for 2D (M0,6) versus 3D and 0.89 (.79-1.01) and 0.75 (.67-.85) for 2D (M0,12) versus 3D. The safety profile was clinically acceptable in all groups.

Conclusions: The 2D regimens for the HPV-16/18 AS04-adjuvanted vaccine in girls aged 9-14 years (M0,6 or M0,12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

Clinical Trials Registration: NCT01381575.

Citing Articles

Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.

Li J, Shi L, Li K, Huang L, Li J, Dong Y Vaccine. 2024; .

PMID: 39492306 PMC: 10680975. DOI: 10.1016/j.vaccine.2023.10.041.

Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials.

Kemin L, Mengpei Z, Jing Z, Rutie Y Front Public Health. 2023; 11:1152057.

PMID: 37808981 PMC: 10552866. DOI: 10.3389/fpubh.2023.1152057.

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults.

LeFevre I, Bravo L, Folschweiller N, Lopez Medina E, Moreira Jr E, Nordio F NPJ Vaccines. 2023; 8(1):75.

PMID: 37230978 PMC: 10208910. DOI: 10.1038/s41541-023-00670-6.

A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand.

Jiamsiri S, Rhee C, Ahn H, Poudyal N, Seo H, Klinsupa W PLoS One. 2022; 17(4):e0267294.

PMID: 35482803 PMC: 9049519. DOI: 10.1371/journal.pone.0267294.

The influence of interval between doses on response to vaccines.

Rodrigues C, Plotkin S Vaccine. 2021; 39(49):7123-7127.

PMID: 34774357 PMC: 8580840. DOI: 10.1016/j.vaccine.2021.10.050.

References

Ault K . Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369(9576):1861-1868. DOI: 10.1016/S0140-6736(07)60852-6. View

Stanley M . Immune responses to human papillomavirus. Vaccine. 2005; 24 Suppl 1:S16-22. DOI: 10.1016/j.vaccine.2005.09.002. View

Block S, Nolan T, Sattler C, Barr E, Giacoletti K, Marchant C . Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118(5):2135-45. DOI: 10.1542/peds.2006-0461. View

Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R . Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171(10):4969-73. DOI: 10.4049/jimmunol.171.10.4969. View

Lazcano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J . Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2013; 32(6):725-32. DOI: 10.1016/j.vaccine.2013.11.059. View

Scott Lamontagne D, Thiem V, Huong V, Tang Y, Neuzil K . Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis. 2013; 208(8):1325-34. DOI: 10.1093/infdis/jit363. View

Garcia-Sicilia J, Schwarz T, Carmona A, Peters K, Malkin J, Tran P . Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health. 2010; 46(2):142-51. DOI: 10.1016/j.jadohealth.2009.11.205. View

Traggiai E, Puzone R, Lanzavecchia A . Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine. 2003; 21 Suppl 2:S35-7. DOI: 10.1016/s0264-410x(03)00198-1. View

Smolen K, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G . Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012; 30(24):3572-9. DOI: 10.1016/j.vaccine.2012.03.051. View

10.

Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Behre U . Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2015; 12(1):20-9. PMC: 4962738. DOI: 10.1080/21645515.2015.1065363. View

11.

Harper D, Franco E, Wheeler C, Ferris D, Jenkins D, Schuind A . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364(9447):1757-65. DOI: 10.1016/S0140-6736(04)17398-4. View

12.

Dessy F, Giannini S, Bougelet C, Kemp T, David M, Poncelet S . Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer.... Hum Vaccin. 2008; 4(6):425-34. DOI: 10.4161/hv.4.6.6912. View

13.

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

14.

Burd E . Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003; 16(1):1-17. PMC: 145302. DOI: 10.1128/CMR.16.1.1-17.2003. View

15.

Harper D, Franco E, Wheeler C, Moscicki A, Romanowski B, Roteli-Martins C . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367(9518):1247-55. DOI: 10.1016/S0140-6736(06)68439-0. View

16.

Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M . Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013; 309(17):1793-802. DOI: 10.1001/jama.2013.1625. View

17.

Romanowski B, Schwarz T, Ferguson L, Ferguson M, Peters K, Dionne M . Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother. 2014; 10(5):1155-65. PMC: 4896558. DOI: 10.4161/hv.28022. View

18.

Jit M, Brisson M, Laprise J, Choi Y . Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ. 2015; 350:g7584. PMC: 4285892. DOI: 10.1136/bmj.g7584. View

19.

Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M . Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011; 103(19):1444-51. PMC: 3186781. DOI: 10.1093/jnci/djr319. View

20.

Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K . Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011; 7(12):1374-86. PMC: 3338934. DOI: 10.4161/hv.7.12.18322. View